Difference between revisions of "Team:Evry"

m
Line 2: Line 2:
 
{{:Team:Evry/Template:SideNavbar}}
 
{{:Team:Evry/Template:SideNavbar}}
 
<html>
 
<html>
 +
    <!-- Main Content -->
 
<div class='side-body hidden-xs parallax' style="width: calc(100%-250px); height: 550px; background-image: url('https://static.igem.org/mediawiki/2015/5/5d/Homepage_header_background_optimized.jpg'); background-size: cover;">
 
<div class='side-body hidden-xs parallax' style="width: calc(100%-250px); height: 550px; background-image: url('https://static.igem.org/mediawiki/2015/5/5d/Homepage_header_background_optimized.jpg'); background-size: cover;">
 
       <div style="position: relative; top: 50%; transform: translateY(-50%);  -webkit-transform: translateY(-50%);">
 
       <div style="position: relative; top: 50%; transform: translateY(-50%);  -webkit-transform: translateY(-50%);">
Line 9: Line 10:
 
</div>
 
</div>
 
         <div class="container">
 
         <div class="container">
 +
        <div class="side-body" id="content-body">
 
<div id='top-menu-anchor'></div>
 
<div id='top-menu-anchor'></div>
 
<div id="top-menu"></div>
 
<div id="top-menu"></div>
 
        <div class="side-body" id="content-body">
 
 
     <div class="page-header">
 
     <div class="page-header">
 
     <h1>Welcome!</h1> <!--  to our project homepage -->
 
     <h1>Welcome!</h1> <!--  to our project homepage -->
Line 18: Line 18:
 
<h2>Abstract</h2>
 
<h2>Abstract</h2>
 
<p class="lead">Reshaping immunotherapy landscape.</p>
 
<p class="lead">Reshaping immunotherapy landscape.</p>
<p class="text-justify" style="font-size: 120%;">Cancer thrives by preventing the immune system from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To address these issues, our team mainly focused on engineering a S. cerevisiae yeast immunotherapy that was ultimately tested <strong>in vivo</strong> on mice presenting melanoma.</p>  
+
<p class="text-justify">Cancer thrives by preventing the immune system from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To address these issues, our team mainly focused on engineering a <em>S. cerevisiae</em> yeast immunotherapy that was ultimately tested <strong>in vivo</strong> on mice presenting melanoma.</p>  
<p class="text-justify" style="font-size: 120%;">Three complementary strategies were combined: First, in order to modulate the tumor environment, yeast secreting immune modulators, GM-CSF and IFNgamma, were encapsulated into alginate beads and injected in tumors. Secondly, to break the immune tolerance against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system. Last, to deliver cytotoxic compounds solely in the tumor environment, a yeast hypoxia bio-sensor was designed. A side project consisted in engineering E. coli to drive MAIT lymphocytes against cancer cells instead of their original targets, parasitized cells.</p>
+
<p class="text-justify">Three complementary strategies were combined: First, in order to modulate the tumor environment, yeast secreting immune modulators, GM-CSF and IFNgamma, were encapsulated into alginate beads and injected in tumors. Secondly, to break the immune tolerance against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system. Last, to deliver cytotoxic compounds solely in the tumor environment, a yeast hypoxia bio-sensor was designed. A side project consisted in engineering E. coli to drive MAIT lymphocytes against cancer cells instead of their original targets, parasitized cells.</p>
<!--p class="lead text-justify">Our immune system can be seen as a balance between immunity and tolerance.
+
This mechanism sometimes fails and lead to deleterious effects:
+
a too important immune response can lead to food allergies or Inflammatory Bowel Disease.
+
Absence of an immune response, in the other hand, plays a role in the spread of cancer cells.</p-->
+
 
<!--div id="img-div"><img src="https://static.igem.org/mediawiki/2015/8/8a/Shcema_immune_syst.jpg" class="img-rounded img-responsive"></img></div-->
 
<!--div id="img-div"><img src="https://static.igem.org/mediawiki/2015/8/8a/Shcema_immune_syst.jpg" class="img-rounded img-responsive"></img></div-->
 
<!--p class="lead">Dendritic cells can orchestrate the immune response. By acting on them using engineered micro-organisms,
 
<!--p class="lead">Dendritic cells can orchestrate the immune response. By acting on them using engineered micro-organisms,
Line 30: Line 26:
 
   <script defer="defer" type="text/javascript">
 
   <script defer="defer" type="text/javascript">
 
   // Scrolling too much = navbar appears.
 
   // Scrolling too much = navbar appears.
$(window).scroll(function() {
+
/*$(window).scroll(function() {
 
     if($(this).scrollTop() > 110) {
 
     if($(this).scrollTop() > 110) {
 
         $('.navbar-fixed-top').removeClass('navbar-transparent');
 
         $('.navbar-fixed-top').removeClass('navbar-transparent');
Line 36: Line 32:
 
         $('.navbar-fixed-top').addClass('navbar-transparent');
 
         $('.navbar-fixed-top').addClass('navbar-transparent');
 
     }
 
     }
});
+
});*/
  
 
// Parallax effect ftw
 
// Parallax effect ftw
Line 52: Line 48:
 
})();
 
})();
 
// Scroll smoothly plz.
 
// Scroll smoothly plz.
    $('a[href="#content-container"]').click(function(){
+
/*    $('a[href="#content-container"]').click(function(){
 
         var the_id = $(this).attr("href");
 
         var the_id = $(this).attr("href");
 
         $('html, body').animate({
 
         $('html, body').animate({
Line 58: Line 54:
 
         }, 'slow');
 
         }, 'slow');
 
         return false;
 
         return false;
});
+
});*/
 
   </script>
 
   </script>
 
<!-- Old content removed ! -->
 
<!-- Old content removed ! -->

Revision as of 00:39, 31 August 2015

Abstract

Reshaping immunotherapy landscape.

Cancer thrives by preventing the immune system from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To address these issues, our team mainly focused on engineering a S. cerevisiae yeast immunotherapy that was ultimately tested in vivo on mice presenting melanoma.

Three complementary strategies were combined: First, in order to modulate the tumor environment, yeast secreting immune modulators, GM-CSF and IFNgamma, were encapsulated into alginate beads and injected in tumors. Secondly, to break the immune tolerance against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system. Last, to deliver cytotoxic compounds solely in the tumor environment, a yeast hypoxia bio-sensor was designed. A side project consisted in engineering E. coli to drive MAIT lymphocytes against cancer cells instead of their original targets, parasitized cells.

Scroll to top To top